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he goal of this panel was to identify key con-
tentious methodology issues in conducting
healthcare pharmacoeconomic evaluations in the
context of clinical studies. Its specific objectives
were to:
• identify and prioritize the key issues associated
with including pharmacoeconomic and out-
comes research projects in clinical studies;
• identify a plan of action to resolve these issues;
• recommend next steps.
 
Background and Context
 
Consumers of pharmacoeconomic information in-
clude patients, clinicians, and, in particular, health-
care decision- and policy-makers in managed care
and government. Evaluations of the costs and out-
comes of various treatment options are in increas-
ing demand to inform formulary and treatment
guideline decision-making. In order to assess the
value, and not just the price, of new interventions,
consumers need data that are both valid and gen-
eralizable. Pharmacoeconomic data used to pro-
vide such evidence of the value of therapeutic in-
terventions can be generated from a variety of
study methodologies.
The strengths and limitations of various clinical
study designs for economic evaluation, particu-
larly randomized controlled trials (RCTs), have
been described elsewhere [1–4]. Briefly, the use of
RTCs to develop pharmacoeconomic data has sev-
eral advantages: these data are based on a well-
established and accepted methodology, are readily
interpretable, have statistical rigor, and can be de-
signed free of most types of bias. The process of
randomization is particularly critical in decreasing
the probability of selection bias. Especially when
studying small effects, other methodologies (e.g.,
observational studies) are less reliable.
The limitations of RCTs have also been recog-
nized. These arise primarily from the costs associ-
ated with carrying out trials with multiple com-
parators, trials of long duration, and trials large
enough to detect infrequent outcomes. In addi-
tion, the prospective nature of RCTs means that
there is a substantial delay between posing a ques-
tion and answering it. Furthermore, it is difficult
to separate protocol-driven costs from actual costs
of care. In many cases, the choice of clinical trial
outcome measures may not be relevant to stan-
dard or usual care. Concern has also been ex-
pressed that when therapies with proven efficacy
are translated to “usual care” settings, the results
may fall short of those predicted by controlled
studies. The outcomes achieved when new inter-
ventions are implemented in actual practice set-
tings are often referred to as evidence of the effec-
tiveness (as distinguished from the efficacy) of that
treatment.
These limitations on the usefulness and the gen-
eralizability of the results from controlled clinical
trials have led to the increased use of alternative
designs, including observational studies, to ad-
dress these problems. The advantages of using ob-
servational studies to collect pharmacoeconomic
data include the ability to follow relatively large
numbers of patients for extended periods of time.
Whereas the outcomes in RCTs sometimes repre-
sent intermediate outcomes, prolonged follow-up
in observational studies allows for capturing long-
term outcomes, including mortality.
Observational designs are often used when
studying the effectiveness of a treatment. Whereas
choice of comparator is often precluded, compara-
tors are generally those used most frequently in
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practice settings, enhancing the generalizability of
study results.
The most serious limitations of observational
studies are methodological. Arguably the greatest
weakness of the observational study is the inabil-
ity to control for selection bias. In addition, strate-
gies to control for confounding variables are lim-
ited.
Users of pharmacoeconomic data need infor-
mation on both the efficacy and effectiveness of
new treatments and how these compare for alter-
native treatments. Although few would argue that
the RCT is the “gold standard” when evaluating
the efficacy of an intervention, it may be possible
to maximize the usefulness of other methods by
controlling for as many confounding variables as
possible. Our understanding of the relative value
of interventions could be advanced by the adop-
tion of study designs chosen to balance scientific
exigencies with practical application.
 
Problem Statement
 
The study methods that are acceptable for demon-
strating drug efficacy are largely agreed upon and
are, in most cases, randomized controlled trials
(RCTs). RCTs have been criticized, however, for
not adequately addressing value in applied set-
tings. In addition, limiting pharmacoeconomic
data to those derived from RCTs would reduce
the body of timely information. Alternative meth-
ods, such as observational studies, utilized by
health economists and epidemiologists for assess-
ing questions of value are often compromised by
methodological inadequacies, particularly selec-
tion bias. Developing a better understanding of
when different methods are appropriate will im-
prove the usefulness and validity of pharmacoeco-
nomic information.
 
Issues
 
This paper addresses four primary issues:
1. Under what circumstances should RTCs be the
primary approach for assessing questions of
value?
2. How can RCTs be modified to improve their
usefulness to inform economic decision-making?
3. Under what circumstances can observational
studies be used to assess questions of value?
4. How can observational studies be modified to
improve their usefulness to inform economic
decision-making?
 
Under What Circumstances Should RCTs Be the 
Primary Approach for Assessing Questions of Value?
 
Pharmacoeconomic data can be derived from ran-
domized trials, but randomized controlled trials
are not always the first choice for a variety of rea-
sons, both practical and scientific. Randomized
controlled trails should be considered the primary
approach, however, under the following circum-
stances:
• The significance of the results justifies the ex-
pense. Not every question merits the level of
assurance that a result is replicable and free
from most types of bias that an RCT can pro-
vide. The “cost-effectiveness” of the study
needs to be evaluated. For example, the Fed-
eral Trade Commission Policy Statement Re-
garding Advertising Substantiation [5] specifi-
cally mentions that the cost of developing the
evidence for substantiation of a cost-effective-
ness conclusion is one of the key issues in de-
ciding the adequacy of the scientific basis for
support. The FTC’s extensive experience in
regulating the promotion of nonprescription
drug claims provides an important perspective
when considering whether to invest in a clini-
cal trial to evaluate the economic impact of a
particular drug.
• There is a reasonable likelihood of observing
patient outcomes within a relatively short time,
and/or intermediate endpoints (e.g., success in
controlling blood pressure) are acceptable.
When RCTs are used to study long-term out-
comes, they can be very costly. Care must be
exercised, however, in extrapolating to long-
term outcomes that have not been causally
linked to intermediate endpoints. When inter-
mediate outcome variables are used, the data
supporting the level of certainty in the link be-
tween the intermediate variable and final out-
comes need to be well established and dis-
closed.
• There is consensus on the appropriate compar-
ator(s). If there is agreement (within a defined
practice setting) that one intervention is the
standard treatment approach, a single large
study (RCT) with a limited number of treat-
ment arms presents a practical approach.
• Effect sizes are predicted to be small, but still
important from a clinical or public health per-
spective. Under these circumstances, observa-
tional studies are of limited usefulness because
the magnitude of the observed effect of the
drug may be similar to the amount of uncon-
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trolled confounding. A randomized controlled
trial will provide the strongest evidence that
the observed differences between treatments
are not due to confounding and that the asso-
ciation between treatment and outcome is one
of cause and effect.
• Randomization is acceptable to (physician) in-
vestigators and to patients.
 
How Can RCTs Be Modified to Improve Their 
Usefulness to Inform Economic Decision-Making?
 
Most of the concern expressed about RCTs, par-
ticularly from decision-makers, is not attributable
to methodological flaws, but to questions about
the generalizability of the results to practice set-
tings. To mitigate these concerns:
• Conduct RCTs in settings where decisions are
made, for example, in managed care organiza-
tions.
• Adopt more naturalistic study designs.
• Liberalize inclusion criteria and minimize ex-
clusion criteria:
• Use active comparators where reasonable.
Placebos are generally perceived by deci-
sion-makers as not pertinent. When ex-
pected measures of effectiveness are less ro-
bust (e.g., in studies of depression), a
placebo comparator may be needed for
credible assessments of effectiveness.
• Use relevant comparators. Select compara-
tors based on community accepted stan-
dard treatments whenever feasible. If the
optimal dose of the comparator agent is
unknown, it may be necessary to test multi-
ple doses.
• Mimic usual care as closely as possible. The
effectiveness of new interventions is critical
to providers, as well as to decision-makers.
Protocol required assessments and follow-
ups should be structured to align as closely
as possible with acceptable community stan-
dards. Whenever possible, the frequency of
those assessments should not be dictated by
the protocol.
• Reduce the burden of adverse event report-
ing, if possible, without compromising pa-
tient safety. For a marketed drug, or even a
drug in late phase III testing, it is not neces-
sary to collect data on all adverse drug
events (ADEs). It would be possible, for ex-
ample, to collect data only on ADEs that
lead to changes in drug dose, medication
switching, an intervention, and/or a prema-
ture termination of a patient from a study.
• Use nested designs. For example, answer sec-
ondary questions in subpopulations if the
power is adequate.
• Report variances around economic measures.
Variance around economic measures has gen-
erally been less adequately described than that
around clinical outcomes, limiting the useful-
ness of this data for decision-makers.
 
Under What Circumstances Can Observational 
Studies Be Used to Assess Questions of Value?
 
Discussion here is limited to observational studies
that use primary data sources. The use of adminis-
trative databases in economic evaluations is ad-
dressed by Panel 3. Primary data in this context
refers to data that are derived from prospectively
defined study questions that specify the particular
endpoints of interest. The data may then come
from a number of sources, including the medical
record or a relevant database.
Observational studies should be considered as
a primary approach when the following criteria
are met:
• The effect size is expected to be large.
• The cost-effectiveness of an RCT is question-
able. (Many of the following circumstances con-
tribute to the unacceptable cost of an RCT.)
• The primary outcome is a rare event. Observa-
tional studies may be a more appropriate ap-
proach for rare outcomes requiring very large
sample sizes. For example, if the true rate of an
event is 0.001 and you want to detect a two-
fold increase in risk, it would be necessary to
follow 40,000 individuals [6]. Randomized
controlled trials of this size are prohibitively
expensive for all but the most important ques-
tions.
• There are multiple appropriate comparators. Var-
iation in clinical practice is a well-described phe-
nomenon and there are often multiple drugs
that can be used to treat a particular condition.
Because relevant comparators typically differ
across practice settings, it is unlikely that all
possible drugs will be evaluated in a random-
ized controlled trial.
• Observation of the primary outcome requires
extended follow-up. This is particularly true
for studies in chronic diseases. Long-term com-
plications of diabetes and rheumatoid arthritis,
for example, often manifest 10–20 years after
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onset of disease. It is neither easy nor practical
to conduct randomized clinical trials for such
long durations. In addition, if there is a consid-
erable loss-to-follow-up over time (as is likely),
then results from an RCT will suffer from va-
lidity as well as prohibitive cost. The only fea-
sible solution under such circumstances is lon-
gitudinal observational studies.
• The intervention to be studied has been avail-
able for a long time and data are available
from multiple sources including government,
third-party payers, and managed care organi-
zations and vendors.
• People are likely to refuse randomization (for
example, comparing invasive procedures to
noninvasive treatments).
• The primary goal of the study is to assess prac-
tice patterns, as is typically the case in cost of
illness studies.
 
How Can Observational Studies Be Modified 
to Improve Their Usefulness to Inform 
Economic Decision-Making?
 
Although the use of good clinical research prac-
tices obviously applies to the conduct of both
RCTs and observational studies, observational
studies are more frequently criticized for method-
ological inadequacies. To address this concern, the
International Society for Pharmacoepidemiology
(ISPE) has developed guidelines for good epidemi-
ology practices for drug, device, and vaccine re-
search in the United States [7]. While acknowledg-
ing the limitations of nonexperimental data, the
ISPE authors conclude that properly conducted
epidemiologic studies provide valuable informa-
tion about the relationship between drugs and hu-
man health. The good epidemiology practices
(GEPs) provide guidance on those issues that are
under the control of the investigator, specifically
data quality, study design, and study conduct. The
GEPs do not dictate specific research methods, but
rather propose minimum practices and procedures
to help ensure the quality of the data used in ob-
servational studies and to provide adequate docu-
mentation of the study design and methods.
We recommend a similar approach be adopted
for the use of observational data in the conduct of
economic evaluations. Emphasis should be placed
on the importance of specifying a priori:
• the research question(s) (which has been hy-
pothesis driven);
• the study design;
• the data collection methods;
• the data analysis plan;
• dissemination plans.
Additional recommendations include replica-
tion of studies in more than one environment, and
adjustment for factors believed to be associated
with assignment of treatment. Analytic rigor for
observational studies involves adjusting for differ-
ences in baseline characteristics across treatment
groups. The measures of association between in-
tervention and outcome should take into account
those factors that are likely to influence treatment
selection or outcome.
 
Recommendations and Next Steps
 
The following areas would benefit from further
methodological development:
• Develop new methods to account for protocol-
related costs (particularly in studies where these
costs cannot be equated across study groups).
• Develop consensus on the definition of usual
care. With the recommendation that trials
should adopt more naturalistic designs, it is
anticipated that the use of “usual care” as a
comparator will continue to increase.
• Explore methods to supplement intent-to-treat
analyses in usual care trials. Not to minimize
the importance of the intent-to-treat analysis,
but there may be research questions important
to decision-makers that may require an alter-
nate or additional analysis. For example, be-
cause economic trials are typically open-label,
there can be a tendency for differential rates of
crossover between treatment arms. Often pa-
tients randomized to usual care have higher
rates of crossover to the new drug treatment
arm, resulting in patients receiving the same
treatment (the new drug) in both arms. In this
situation useful information can still be de-
rived from subgroup analyses of completers.
• Address problems of pooling economic data
from multiple study sites. This is particularly
problematic in studies when significant differ-
ences in practice styles exist across study sites
(e.g., urban and rural sites, Veterans’ Adminis-
tration and managed care settings). This prob-
lem is exacerbated in international studies
where data are collected across countries.
• Improve statistical methods for adjusting for
selection bias, which is a major drawback of
observational studies. There are several meth-
ods to reduce this bias, from commonly used
techniques such as adjustment by analysis of
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covariance or other multivariate techniques, to
more sophisticated techniques such as instru-
mental variables, two-stage regressions, and
propensity scores. More research is needed to
determine when a particular technique is ap-
propriate for pharmacoeconomic analysis.
• Use better methods for estimating variance
around resource utilization and cost. Tradi-
tional approaches that assume independence of
observations and a normal Gaussian distribu-
tion are unsuitable for calculating variance
around economic parameters. Techniques such
as boot strapping and jack-knifing can be used
in these scenarios. These resampling methods
are also useful in estimating variances around
cost-effectiveness ratios.
• Conduct systematic comparisons of RCTs and
observational studies of the same interven-
tions. It would be useful whenever an RCT is
used to answer a pharmacoeconomic question
to also carry out observational studies of the
same issues to look at correlation, to explain
differences, etc.
• Explore approaches from other disciplines (e.g.,
psychology, sociology, marketing research) to
enhance current methods, particularly in the
areas of data collection, instrumentation, and
analytic techniques.
• Measure resource utilization in large simple
trials. Resources currently dedicated to mar-
keting studies could be reallocated for the
identification and collection of relevant eco-
nomic data.
• Create better methods of measuring direct
medical costs that are not routinely captured
(e.g., nursing time, telephone care).
• Create better methods of measuring relevant
indirect costs (e.g., caregiver, lost productiv-
ity). Pharmacoeconomic analyses are often
conducted from a payer’s viewpoint, ignoring
indirect costs. Yet time lost from work, lost
productivity, caregiver expenses, etc., are im-
portant to the patient and to society. There
needs to be a greater appreciation of these cost
drivers, and simple, easy methods to measure
and document them.
• Encourage inclusion of standardized outcome
measures in the evolving electronic medical
record.
 
Summary
 
Useful pharmacoeconomic data can be derived
from RCTs and observational studies. There is,
however, no single pharmacoeconomic study that
will establish the value of an intervention. Differ-
ent audiences bring a variety of perspectives, as
well as definitions of value, to the generation,
framing, and interpretation of research questions.
Establishing value can result from the synthesis of
data from a variety of sources, including RCTs,
observational studies, and modeling, with appro-
priate attention to the weaknesses and limitations
of each kind of data.
The most important factors for a researcher to
consider in designing a clinical trial to answer
questions of value are knowing the precise ques-
tion(s) that the study is required to answer and
knowing the informational needs of the target au-
dience. Over the long term, it is recommended
that effort be directed towards better consensus
and a greater degree of standardization of defini-
tions and methodologies for assessing health eco-
nomic questions through clinical studies.
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